Bullish
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Karyopharm Therapeutics Inc. will present positive results from its Phase 3 SENTRY trial for selinexor plus ruxolitinib in myelofibrosis at the ASCO 2...